Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (intravenous: 500mg)
Drug ClassLipoglycopeptide antibacterials
Ongoing and
Completed Studies


  • Indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Dalbavancin (Dalvance) is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive microorganisms, showing favorable efficacy against multi-drug-resistant organisms in various age groups, including newborns.
  • Six systematic reviews/meta-analyses were analyzed regarding Dalbavancin's effectiveness, safety, and comparison with other antibiotics.
  • In terms of treating ABSSSIs, Dalbavancin demonstrated similar clinical effectiveness to vancomycin and linezolid, with two doses of Dalbavancin showing a more favorable global microbiological assessment than a single dose, especially against methicillin-resistant and susceptible Staphylococcus aureus.
  • Compared to commonly utilized antibiotics for Gram-positive bacteria infections, Dalbavancin displayed similar clinical responses but was superior in treating catheter-related bloodstream infections (CRBSIs) and osteomyelitis subgroups.
  • A study revealed that Dalbavancin has a comparable safety profile, with fewer treatment emergent adverse effects reported than with other treatments. Specifically, lower mortality rates were observed compared to other antibiotic treatments, while the dual-dose regimen resulted in fewer adverse events, including reduced incidence of diarrhea.
  • Dalbavancin exhibited potent activity against MRSA isolates, suggesting its strong antibacterial properties as an effective option for MRSA infection treatment. Furthermore, novel glycopeptides like Dalbavancin were associated with significantly fewer adverse events compared to vancomycin, indicating a better safety profile, particularly relevant given the high concern for nephrotoxicity common with vancomycin use.

Product Monograph / Prescribing Information

Document TitleYearSource
Dalvance (dalbavancin) prescribing information.2021Allergan USA, Inc., Madison, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines